APR July/August 2023 - 8

CNPerspectives
American Pharmaceutical Review is one of several outstanding publications available from CompareNetworks, Inc.
Here is a look at the insightful content our readers may enjoy from four of our sister resources:
Pharmaceutical Outsourcing, Biocompare, Labcompare, and Tablets & Capsules.
How to De-Risk Clinical Trials in Today's Complex Environment
As the biopharmaceutical industry continues to face extraordinary challenges, it is becoming increasingly
important for companies to identify strategic ways to balance managing financial risks with testing drugs that have the greatest potential for
health impact. With this in mind, we need to better understand why the clinical trials landscape is becoming increasingly volatile, and what
effect that may have in the future.
bit.ly/43FgpgY
A Guide to Endothelial Cell Markers
Endothelial cells line the interior surface of the circulatory system, forming a barrier that regulates the transport of fluids, substances, and
cells to and from various tissues. This system includes blood vessels, which transport nutrients and oxygen to tissues throughout the body,
and lymphatic vessels, which drain interstitial fluid; both serve as conduits for immune cell trafficking. Although most validated endothelial
cell markers label blood vessel endothelial cells and lymphatic endothelial cells indiscriminately, some label lymphatic cells exclusively.
Emerging datasets generated by next-generation sequencing have uncovered novel endothelial markers, enabling the identification of new
endothelial subsets. However, whether these transcriptional markers are suitable for protein detection methods remains to be seen.
bit.ly/3Dt8BEM
Targeting the Undruggable: Methods to Enhance
Targeted Protein Degrader Discovery, Optimization
Abnormal protein expression or activity has been linked to the development of many devastating conditions, including cancer,
autoimmune diseases, and neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington's. These conditions often involve
the misfolding, aggregation, or accumulation of proteins, leading to cellular dysfunction and disease pathology. What if these diseasecausing
proteins could be selectively eliminated to potentially cure the condition? This is the premise behind targeted protein degradation
(TPD), an emerging drug modality that offers the potential to probe biological pathways and target proteins that have previously been
considered " undruggable. "
bit.ly/44Fcrq2
Re: 'Sourcing': Qualifying Excipient Vendors Can
Strengthen Supply Chain
Qualifying multiple, interchangeable sources of excipients used in the manufacture of a drug product could reduce the potential impact of
future global supply chain disruptions. However, careful consideration must be taken to ensure that unintended consequences do not result
from limited evaluation of alternative sources. There are other good business reasons that qualification of multiple excipient sources should
be considered during the drug product lifecycle-from formulation development, through commercial manufacturing.
bit.ly/44F7kGk
8 |
| July/August 2023

http://bit.ly/43FgpgY http://bit.ly/3Dt8BEM http://bit.ly/44Fcrq2 http://bit.ly/44F7kGk

APR July/August 2023

Table of Contents for the Digital Edition of APR July/August 2023